Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 (PROVENT)
NCT04625725Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Nov 2020; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04625725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625725.